Hop­ing to shake Al­ler­gan/Shire's dry eye dom­i­nance, Oys­ter Point posts pos­i­tive Phase IIb da­ta for ri­val drug

7 years ago
R&D

FDA lays down the law on gene ther­a­py, of­fer­ing guid­ances on both dis­eases and pro­ce­dures

7 years ago
Pharma
Cell/Gene Tx

Ra­maswamy’s Der­ma­vant bags GSK’s PhI­II-ready pso­ri­a­sis drug in $330M deal — eye­ing a ma­jor league con­test

7 years ago
R&D
Pharma

Park­er In­sti­tute sci­en­tists her­ald a cell ther­a­py break­through in the lab, us­ing next-gen CRISPR tech to en­gi­neer T ...

7 years ago
Cell/Gene Tx

Gen­mab puts down $54M for im­munother­a­py col­lab­o­ra­tion — ready to spend mil­lions more

7 years ago
Pharma

VC mon­ey booms in Q2, with mega-deals hit­ting record lev­els

7 years ago
Pharma

Thiel-backed Com­pass adds $49M to A round, bring­ing to­tal to $132M

7 years ago
Financing
Startups

Sen­a­tor Wyden prods Trump/Pfiz­er for de­tails, call­ing drug pric­ing stunt 'long on the­atrics, short on re­lief'

7 years ago
Pharma

No­var­tis joins the Big Phar­ma ex­o­dus out of an­tibi­otics, dump­ing re­search, cut­ting 140 and out-li­cens­ing pro­grams

7 years ago
R&D

Bris­tol-My­ers Squib­b's Op­di­vo/Yer­voy com­bo scores col­orec­tal can­cer OK; For­mer Ake­bia, Mer­ri­mack staffers found ...

7 years ago
News Briefing

Pfiz­er reshuf­fles, split­ting in­to three busi­ness units

7 years ago
Pharma

12 top Chi­na VCs you need to know who are mak­ing a transpa­cif­ic splash (Part 2)

7 years ago
Financing
China

No­var­tis punts a late-stage PI3K drug with a wor­ry­ing safe­ty pro­file to one of Chi­na’s up­start biotechs

7 years ago
R&D
Pharma

Ot­su­ka jumps in­to the US biotech M&A game, bag­ging Vis­ter­ra in $430M buy­out

7 years ago
Deals

Trump claims a big win over Big Phar­ma, forc­ing Pfiz­er to walk back drug price hikes

7 years ago
Pharma

For­bion rais­es $316M to tap the po­ten­tial of Eu­ro­pean biotech plays

7 years ago
Financing

Un­der pres­sure from share­hold­ers, BioCryst drops plan to merge with Idera

7 years ago
Deals

Chi­na's Tasly Bio­phar­ma turns a de­vel­op­ment part­ner in­to an in­vestor as it preps Hong Kong IPO

7 years ago
China
Pharma

Caught in a reg­u­la­to­ry lim­bo fol­low­ing FDA hold, EMA spurns Ad­vax­is’ ef­fort to seek con­di­tion­al OK

7 years ago
Pharma

Genen­tech vet Myr­tle Pot­ter takes a lead­ing role in Vivek Ra­maswamy's fast-mov­ing Vant ops

7 years ago
People
R&D

An­ti­body mak­er Vac­cinex files $46M IPO tout­ing I/O com­bo drug; Replimune shoots for $100M-plus in IPO

7 years ago
News Briefing

As biotech funds sprout around the globe, Sanofi and gov­ern­ment bank are set­ting up a $292M op­er­a­tion in France

7 years ago
Financing

7 things you need to know now about rais­ing biotech cash in Chi­na (Part 1)

7 years ago
Financing
China

Penn team-biotech col­lab­o­ra­tion high­lights promise of gene edit­ing in tar­get­ing PC­SK9, liv­er dis­eases

7 years ago
Discovery
Cell/Gene Tx
First page Previous page 1013101410151016101710181019 Next page Last page
A service from the Financial Times